S2 Episode 6: Can the Use of ADCs in Breast Cancer Teach Us About Resistance Mechanisms and Sequencing in Endometrial Cancer?
Drs Ursula A. Matulonis and Leif W. Ellisen discuss endometrial cancer and ADCs, including resistance mechanisms, ADC sequencing, what's exciting in the field, and novel payloads. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1001983. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Endometrial Carcinoma https://emedicine.medscape.com/article/254083-overview The Clinical Landscape of Antibody-Drug Conjugates in Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/39074933/ FDA Grants Accelerated Approval to Fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic HER2-Positive Solid Tumors https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2 Mechanisms of Resistance to Antibody-Drug Conjugates https://pubmed.ncbi.nlm.nih.gov/36831621/ TOP1 Mutations and Cross-Resistance to Antibody-Drug Conjugates in Patients With Metastatic Breast Cancer https://pubmed.ncbi.nlm.nih.gov/39745368/ Single-Cell Analysis Technologies for Cancer Research: From Tumor-Specific Single Cell Discovery to Cancer Therapy https://pubmed.ncbi.nlm.nih.gov/37900181/ Spatial Transcriptomics for Tumor Heterogeneity Analysis https://pubmed.ncbi.nlm.nih.gov/35899203/ Exploring Circulating Tumor DNA (CtDNA) and Its Role in Early Detection of Cancer: A Systematic Review https://pmc.ncbi.nlm.nih.gov/articles/PMC10516512/ Current and Emerging Prognostic Biomarkers in Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/35530346/ Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer https://pubmed.ncbi.nlm.nih.gov/34404686/ Antibody-Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients With Breast Cancer https://pubmed.ncbi.nlm.nih.gov/38709212/ Antibody-Drug Conjugates as Targeted Therapy for Treating Gynecologic Cancers: Update 2025 https://pubmed.ncbi.nlm.nih.gov/39480912/
--------
26:20
--------
26:20
S2 Episode 5: The Future of Replication Stress and DNA Damage and Repair in Endometrial Cancer
Drs Ursula A. Matulonis and Joyce F. Liu discuss targeting DNA damage and repair and replication stress in endometrial cancer. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1001982. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Endometrial Carcinoma https://emedicine.medscape.com/article/254083-overview Exploiting Replicative Stress in Gynecological Cancers as a Therapeutic Strategy https://pubmed.ncbi.nlm.nih.gov/32571890/ Mechanisms of Oncogene-Induced Replication Stress: Jigsaw Falling Into Place https://pubmed.ncbi.nlm.nih.gov/29653955/ WEE1 Inhibition in Cancer Therapy: Mechanisms, Synergies, Preclinical Insights, and Clinical Trials https://pubmed.ncbi.nlm.nih.gov/40187712/ Phase 2 Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma https://pubmed.ncbi.nlm.nih.gov/33705205/ ADAGIO: A Phase 2b, Open-Label, Single-Arm, Multicenter Study Assessing the Efficacy and Safety of Adavosertib (AZD1775) as Treatment for Recurrent or Persistent Uterine Serous Carcinoma https://ascopubs.org/doi/10.1200/JCO.2021.39.15_suppl.TPS5612 Azenosertib Monotherapy Yields Encouraging Responses in Cyclin E1+ Proc https://www.cancernetwork.com/view/azenosertib-monotherapy-yields-encouraging-responses-in-cyclin-e1-proc Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase 3 Duo-E Trial https://pubmed.ncbi.nlm.nih.gov/37864337/ Homologous Recombination Deficiency: Concepts, Definitions, and Assays https://pubmed.ncbi.nlm.nih.gov/35274707/ A Replication Stress Biomarker Is Associated With Response to Gemcitabine vs Combined Gemcitabine and ATR Inhibitor Therapy in Ovarian Cancer https://pubmed.ncbi.nlm.nih.gov/34552099/ Abstract B144: Discovery and Preclinical Evaluation of Novel Oral WEE1 Degraders https://aacrjournals.org/mct/article/22/12_Supplement/B144/730300/Abstract-B144-Discovery-and-preclinical-evaluation
--------
26:11
--------
26:11
S2 Episode 4: Endometrial Cancer Trends: Immunotherapy Insights and Research Priorities
Drs Ursula A. Matulonis and Gini Fleming discuss the state of endometrial cancer, the role of immunotherapy, and priorities for research in this field. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1001981. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Cancer Statistics, 2025 https://pubmed.ncbi.nlm.nih.gov/39817679/ Racial and Ethnic Differences in Hysterectomy-Corrected Uterine Corpus Cancer Mortality by Stage and Histologic Subtype https://pubmed.ncbi.nlm.nih.gov/35511145/ The Advent of Immune Checkpoint Inhibition for the Treatment of Patients With Primary Advanced or Recurrent dMMR/MSI High Endometrial Cancer in 2025 https://pubmed.ncbi.nlm.nih.gov/39611619/ Overall Survival in Patients With Endometrial Cancer Treated With Dostarlimab Plus Carboplatin-Paclitaxel in the Randomized ENGOT-EN6/GOG-3031/RUBY Trial https://pubmed.ncbi.nlm.nih.gov/38866180/ Safety and Antitumor Activity of Dostarlimab in Patients With Advanced or Recurrent DNA Mismatch Repair Deficient/Microsatellite Instability-High (dMMR/MSI-H) or Proficient/Stable (MMRp/MSS) Endometrial Cancer: Interim Results From GARNET-A Phase I, Single-Arm Study https://pubmed.ncbi.nlm.nih.gov/35064011/ A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined With Either Trastuzumab and Hyaluronidase-Oysk (Herceptin Hylecta) or Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf (Phesgo) in Her2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma https://www.nrgoncology.org/Clinical-Trials/Protocol/nrg-gy026?filter=nrg-gy026 A New Vision for Women's Health Research: Transformative Change at the National Institutes of Health https://pubmed.ncbi.nlm.nih.gov/39652697/ Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial https://pubmed.ncbi.nlm.nih.gov/37870536/ Antibody-Drug Conjugates as Targeted Therapy for Treating Gynecologic Cancers: Update 2025 https://pubmed.ncbi.nlm.nih.gov/39480912/ A Phase II Study of Frontline Paclitaxel/Carboplatin/Bevacizumab, Paclitaxel/Carboplatin/Temsirolimus, or Ixabepilone/Carboplatin/Bevacizumab in Advanced/Recurrent Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/29804638/
--------
23:03
--------
23:03
S2 Episode 3: Endometrial Cancer: Molecular Classification, Genetics, When to Rebiopsy, and What's New in the Research
Drs Ursula A. Matulonis and Katherine Fuh discuss the molecular classification and genetics of endometrial cancer as well as when to rebiopsy, research updates, and what's to come in the future. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1001980. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Endometrial Carcinoma https://emedicine.medscape.com/article/254083-overview Molecular Classification of Endometrial Cancer and the 2023 FIGO Staging: Exploring the Challenges and Opportunities for Pathologists https://pubmed.ncbi.nlm.nih.gov/37627129/ Molecular Testing for Endometrial Cancer: An SGO Clinical Practice Statement https://pubmed.ncbi.nlm.nih.gov/36399812/ TCGA Molecular Prognostic Groups of Endometrial Carcinoma: Current Knowledge and Future Perspectives https://pubmed.ncbi.nlm.nih.gov/36232987/ Histopathological Characterization of ProMisE Molecular Groups of Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/31932106/ Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02 https://pubmed.ncbi.nlm.nih.gov/39261417/ Randomized Phase III Trial of Radiation Therapy With or Without Pembrolizumab for Women With High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer (NRG-GY020) https://www.nrgoncology.org/Home/News/Post/randomized-phase-iii-trial-of-radiation-therapy-with-or-without-pembrolizumab-for-women-with-high-intermediate-risk-mismatch-repair-deficient-dmmr-endometrioid-endometrial-cancer-nrg-gy020 Testing Strategies for Lynch Syndrome in People With Endometrial Cancer https://www.medscape.co.uk/viewarticle/testing-strategies-lynch-syndrome-people-endometrial-cancer-2023a10001yb Endometrial Cancer at Recurrence: To Re-sequence or Not to Re-sequence https://pubmed.ncbi.nlm.nih.gov/38841264/ Molecular Profiling of Primary Endometrioid Endometrial Cancer and Matched Lung Metastases: CTNNB1 Mutation as a Potential Driver https://pubmed.ncbi.nlm.nih.gov/38633674/ Route 66 Endometrial Cancer SPORE https://trp.cancer.gov/spores/abstracts/wustl_endometrial.htm Project 2: Inhibiting AXL to Improve Treatment Response in Endometrial Cancer https://trp.cancer.gov/spores/abstracts/wustl_endometrial.htm#h04 AXLerate-OC/GOG-3059/ENGOT OV-66: Results of a Phase 3, Randomized, Double-Blind, Placebo/Paclitaxel-Controlled Study of Batiraxcept (AVB-S6-500) in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer https://ascopubs.org/doi/10.1200/JCO.2024.42.17_suppl.LBA5515 Inhibition of AXL and VEGF-A Has Improved Therapeutic Efficacy in Uterine Serous Cancer https://pubmed.ncbi.nlm.nih.gov/34884986/ GOG Foundation Overview https://www.gog.org/about/
--------
25:53
--------
25:53
S2 Episode 2: Endometrial Cancer Disparities: Improving Black Women's Access to Care and Trials
Drs Ursula A. Matulonis and Eloise Chapman-Davis discuss overcoming health disparities in endometrial cancer and increasing clinical trial enrollment of Black women. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1001979. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Endometrial Carcinoma https://emedicine.medscape.com/article/254083-overview Cancer Statistics, 2025 https://pubmed.ncbi.nlm.nih.gov/39817679/ An Intervention-Based Approach to Achieve Racial Equity in Gynecologic Oncology https://pubmed.ncbi.nlm.nih.gov/37678907/ Patient Navigation in Cancer Treatment: A Systematic Review https://pubmed.ncbi.nlm.nih.gov/38581470/ Disparities in the Allocation of Research Funding to Gynecologic Cancers by Funding to Lethality Scores https://pubmed.ncbi.nlm.nih.gov/30404721/ ECANA https://www.ecanawomen.org/ Racial Disparities in Diagnostic Evaluation of Uterine Cancer Among Medicaid Beneficiaries https://pubmed.ncbi.nlm.nih.gov/36788453/ Lenvatinib Plus Pembrolizumab for Advanced Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/35045221/ MedExplain https://medexplain.org/ PALS for Health https://www.palsforhealth.org/
Listen to Medscape InDiscussion: Endometrial Cancer, a podcast series where thought leaders and clinical experts share their diverse insights and practical ideas for optimizing patient care. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/999848. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Portugal